Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;80(2):221-34.
doi: 10.1111/bcp.12621. Epub 2015 Jun 8.

Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review

Sophie West  1 , Praveen Bhugra  1
Affiliations

Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review

Sophie West et al. Br J Clin Pharmacol. 2015 Aug.

Abstract

Aims: Currently, treatment for Alzheimer's disease (AD) focuses on the cholinergic hypothesis and provides limited symptomatic effects. Research currently focuses on other factors that are thought to contribute to AD development such as tau proteins and Aβ deposits, and how modification of the associated pathology affects outcomes in patients. This systematic review summarizes and appraises the evidence for the emerging drugs affecting Aβ and tau pathology in AD.

Methods: A comprehensive, systematic online database search was conducted using the databases ScienceDirect and PubMed to include original research articles. A systematic review was conducted following a minimum set of standards, as outlined by The PRISMA Group . Specific inclusion and exclusion criteria were followed and studies fitting the criteria were selected. No human trials were included in this review. In vitro and in vivo AD models were used to assess efficacy to ensure studied agents were emerging targets without large bodies of evidence.

Results: The majority of studies showed statistically significant improvement (P < 0.05) of Aβ and/or tau pathology, or cognitive effects. Many studies conducted in AD animal models have shown a reduction in Aβ peptide burden and a reduction in tau phosphorylation post-intervention. This has the potential to reduce plaque formation and neuronal degeneration.

Conclusions: There are many emerging targets showing promising results in the effort to modify the pathological effects associated with AD. Many of the trials also provided evidence of the clinical effects of such drugs reducing pathological outcomes, which was often demonstrated as an improvement of cognition.

Keywords: Alzheimer's disease; Aβ; emerging targets; systematic review; tau.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Algorithm of the method followed to identify the studies to be included in the review (adapted from The PRISMA Group 1)
See this image and copyright information in PMC

References

    1. The PRISMA Group. Transparent reporting of systematic reviews and meta-analyses. 2009. Available at http://www.prisma-statement.org/statement.htm (last accessed 3 April 2014)
    1. Alzheimer’s Society. Dementia 2013 Infographic. 2014. Available at http://www.alzheimers.org.uk/infographic (last accessed 21 February 2014)
    1. Li SY, Wang XB, Kong LY. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer’s disease. Eur J Med Chem. 2014;71:36–45. - PubMed
    1. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84:361–84. - PubMed
    1. Hernandez F. Gomez de Barreda E, Fuster-Matanzo A. GSK3: A possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010;223:322–5. - PubMed

Publication types

MeSH terms